Haleos Labs (NSE:HALEOSLABS) ROCE %: 3.12% (As of Mar. 2026)


NSE:HALEOSLABS Haleos Labs Ltd NSE:HALEOSLABS
72 GF Score
Price ₹1,612.30
GF Value ₹1,123.78
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Haleos Labs ROCE %?

Haleos Labs NSE:HALEOSLABS -0.50% 72 ROCE % is 3.12% as of Mar. 2026. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,123.78 (Significantly Overvalued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Haleos Labs's annualized ROCE % for the quarter that ended in Mar. 2026 was 3.12%.

Haleos Labs  (NSE:HALEOSLABS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Haleos Labs ROCE % Related Terms

Haleos Labs ROCE % Historical Data

* Premium members only.

The historical data trend for Haleos Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleos Labs ROCE % Chart

Haleos Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.77 9.54 7.81 14.13 11.59

Haleos Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.62 14.34 15.97 16.31 3.12
NSE:HALEOSLABS
72GF Score
Haleos Labs Ltd NSE:HALEOSLABS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleos Labs ROCE % Calculation

Haleos Labs's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=316.416/( ( (3899.911 - 1420.675) + (4544.084 - 1562.775) )/ 2 )
=316.416/( (2479.236+2981.309)/ 2 )
=316.416/2730.2725
=11.59 %

Haleos Labs's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=93.036/( ( (0 - 0) + (4544.084 - 1562.775) )/ 1 )
=93.036/( ( 0 + 2981.309 )/ 1 )
=93.036/2981.309
=3.12 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 3.12% mean?
Haleos Labs (NSE:HALEOSLABS) has a ROCE % of 3.12% as of Mar. 2026.
Is Haleos Labs' ROCE % too high?
Haleos Labs' current ROCE % is 3.12%. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' ROCE % compare to VRTX and REGN?
Haleos Labs' ROCE % of 3.12% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Haleos Labs's current ROCE % is 3.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,123.78, compared to a current price of ₹1,612.30 — trading 43.5% above its estimated fair value. The current ROCE % is 3.12%. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current ROCE % is 3.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?

Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued. The current stock price of ₹1,612.30 is trading 43.5% above its estimated GF Value™ of ₹1,123.78. GuruFocus considers Haleos Labs to be Significantly Overvalued.

Key valuation signals for NSE:HALEOSLABS:

  • ROCE %: 3.12%
  • GF Value™: ₹1,123.78 vs. price of ₹1,612.30 (43.5% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleos Labs Business Description

Other Exchanges 540679:India
Address Road Number 71, Plot Number 19 - III, Opposite Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad, TG, IND, 500096
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score

Get the complete analysis for NSE:HALEOSLABS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,612.30
Price
₹1,123.78
GF Value